Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies? - Wikidata - wikimedia - TriplyDB

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

http://www.wikidata.org/entity/Q30423909

about

Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies Cell-targeting antibodies in immunity to Ebola Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia.Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients.Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia.Novel multifunctional antibody approved for the treatment of breast cancer.

P2860

Q26849243-23DD9271-37C3-4179-9D33-AF908415BD8E Q27694769-827E6F6E-9E67-4C8A-97DD-485159DA5186 Q28068972-397707A1-45F1-4C04-B623-E2A22207D572 Q28535043-860C3DD8-C090-4571-9409-7D3C63A148C8 Q30276243-42241C03-4643-46B9-8FDC-40409368CBB5 Q30405847-DB72B44A-3537-4601-8C71-50F251EE984B Q30417730-1CB7A37D-E2B2-439C-B545-CF7E88CA0FCF Q36437030-0AFBD11F-228E-452B-9DE3-7021C5CF521A Q38542034-E27B261D-31F5-4584-85E4-76F3DC0652CD Q39834269-C062802E-EA58-4827-9478-13B7998D3F00 Q40519355-4B15FCC2-4907-41AF-B138-C5EF1A0AF085 Q40930170-CE6E71E2-5B5F-42B8-9C91-281F9AB717B0

P2860

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

http://www.wikidata.org/entity/Q30423909

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Monoclonal antibody (mAb)-base ...... reevaluate dosing strategies?

@ast

Monoclonal antibody (mAb)-base ...... reevaluate dosing strategies?

@en

type

label

Monoclonal antibody (mAb)-base ...... reevaluate dosing strategies?

@ast

Monoclonal antibody (mAb)-base ...... reevaluate dosing strategies?

@en

prefLabel

Monoclonal antibody (mAb)-base ...... reevaluate dosing strategies?

@ast

Monoclonal antibody (mAb)-base ...... reevaluate dosing strategies?

@en

P1433

Q30423909-8B12B86A-8CE6-43A7-A1B0-1EA121E54921

P1476

Q30423909-E783AB25-567A-4B7B-B7C4-42FFD71734D0

P2093

Q30423909-284A532E-3FE3-4DB8-9389-A82ED7B9B856

Q30423909-2BF38842-8BCE-40DF-AE44-B67C3BE6E11E

Q30423909-8AB0FA25-4FFE-433C-9AFE-F04344E54F93

Q30423909-A67B452C-9611-410B-93AC-21CCC7BE176D

P2860

Q30423909-07F025DB-6895-4BA6-B63F-A6D0D66AA2E7

Q30423909-3BB68798-778A-471A-921B-F7B9FC90BE2B

Q30423909-4AA65DE7-36AA-4D92-9D84-CA92DF9B9C8C

Q30423909-65AEEBFE-D1DF-4641-BDEC-6609E34051C9

Q30423909-65F1E6B3-AC7A-4463-A634-366C8C1225D5

Q30423909-66F7D48D-0A07-4FFC-AF8C-44F173EF93C9

Q30423909-A737501C-33A8-40CE-BBA9-3544CDABB80D

Q30423909-CA8DB3CB-6D7B-4667-BD0F-4A69811E732B

Q30423909-DC65AA41-B697-430A-92DB-01595C4B4BB9

P304

Q30423909-8B8F1EE1-F5C2-4215-B11B-A5D6325EB82C

P31

Q30423909-E1B1D8E6-70E3-45A3-A9E5-F1F19764AA42

P356

Q30423909-0B5F1A5E-E130-4824-89EC-6283A1340950

P433

Q30423909-2C4C1CA5-C26C-40CD-9282-348D53674413

P478

Q30423909-5D668826-3B9A-42F7-BEB1-8F5D04E818D8

P577

Q30423909-65FAA1DD-A528-4270-B647-CEDE6EA767AE

P5875

Q30423909-ADFA3419-5488-4542-9BF1-5BB13DA653C6

P698

Q30423909-997A0729-B406-4806-BC05-8E3D4F6CE7DD

P921

Q30423909-1C4DF1EE-F8F9-4B81-9467-9B9A58245AB6

P932

Q30423909-D3A1A38A-8979-4C75-9ACB-E19ACEA4F01E

P356

P1433

P1476

Monoclonal antibody (mAb)-base ...... reevaluate dosing strategies?

@en

P2093

Adrian Wiestner

http://www.w3.org/2001/XMLSchema#string

Clive S Zent

http://www.w3.org/2001/XMLSchema#string

Margaret A Lindorfer

http://www.w3.org/2001/XMLSchema#string

Ronald P Taylor

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.

Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients

Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab.

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.

Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites.

Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays.

In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.

P304

959-961

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/ONCI.20368

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233539962

http://www.w3.org/2001/XMLSchema#string

P698

23162771

http://www.w3.org/2001/XMLSchema#string

P921

P932

3489759

http://www.w3.org/2001/XMLSchema#string